Ergomed plc Total Voting Rights and Block Listing Return (9243Q)
July 01 2022 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 9243Q
Ergomed plc
01 July 2022
Total Voting Rights and Block Listing Return
Total Voting Rights
Guildford, UK - 1 July 2022 : In accordance with the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules
("DTRs"), Ergomed plc (the "Company") announces the following
information.
The Company's issued share capital as at 30 June 2022 consisted
of 49,880,029 shares of 1p each, none of which were held in
treasury. Each ordinary share in the capital of the Company carries
one voting right.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company, under the DTRs.
Block Listing Six Monthly Return
Name of applicant: Ergomed plc
Name of scheme: Ergomed plc Long Term Incentive Plan
-------------------------------------------------------------
Period of return: From: 1 January 2022 To: 30 June 2022
-------------------------- -------------------------- ------- ------------------------
Balance of unallotted securities under scheme(s) from
previous return: 1,908,177
-------------------------------------------------------------
Plus: The amount by which the block scheme(s) has been
increased since the date of the last
return (if any increase has been applied for): 0
-------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): 586,400
-------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 1,321,777
-------------------------------------------------------------
Number and class of securities originally admitted and 1,800,000 ordinary shares of 1p each - 2 July 2018
the date of admission 1,500,000 ordinary shares of 1p each - 31 December 2019
600,000 ordinary shares of 1p each - 7 July 2021
-------------------------------------------------------------
Total number of securities in issue at the end of the 49,880,029 ordinary shares of 1p each
period
-------------------------------------------------------------
Name of contact: Fiona Mundy - Director of Group Reporting
Telephone number of contact: +44 (0) 7854825324
------------------------------------------
ENDS
Enquiries :
Ergomed plc Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets &
Strategy)
Numis Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO) and mission-critical regulatory compliance and consulting
services under the ADAMAS brand. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRBBLLXLQLFBBL
(END) Dow Jones Newswires
July 01, 2022 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024